Entry0.8→Now0.7462
Long IVVD into Phase 3 VYD2311 readout Open original source
IVVD Invivyd, Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
17:27
Sep 13
Sep 13
Long IVVD into Phase 3 VYD2311 readout
Author argues Invivyd's risk/reward is compelling ahead of late-Q3 Phase 3 top-line data for next-gen COVID antibody VYD2311 across the DECLARATION efficacy and LIBERTY side-effect comparison trials. Management upsized DECLARATION by ~500 patients, which the author reads as confidence in statistical power, and a favorable LIBERTY result versus mRNA shots could open a large market of vaccine-avoidant patients. IVVD already generates revenue from first-gen antibody PEMGARDA, and the Board Chair stepping into the CEO role suggests preparation for commercial execution or strategic positioning. A clean readout would position VYD2311 for a BLA filing and, given the low valuation and micro-cap dynamics, could trigger a rapid re-rate toward analyst price targets.
HIGH
About IVVD Investor Commentary
Across the available history and selected sources, Buzzberg tracks IVVD (Invivyd, Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/justinrosser.